Evogene (NASDAQ:EVGN) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Evogene (NASDAQ:EVGNFree Report) in a research note published on Sunday morning. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital dropped their price objective on Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, August 23rd.

Check Out Our Latest Stock Analysis on EVGN

Evogene Price Performance

EVGN opened at $1.96 on Friday. The stock has a market capitalization of $10.52 million, a price-to-earnings ratio of -0.49 and a beta of 1.43. The business has a fifty day moving average price of $2.57 and a 200 day moving average price of $4.70. Evogene has a 12 month low of $1.70 and a 12 month high of $10.40.

Evogene (NASDAQ:EVGNGet Free Report) last issued its earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.94). Evogene had a negative net margin of 210.26% and a negative return on equity of 72.33%. The firm had revenue of $0.91 million during the quarter.

Institutional Trading of Evogene

A hedge fund recently raised its stake in Evogene stock. BNP Paribas Financial Markets boosted its position in shares of Evogene Ltd. (NASDAQ:EVGNFree Report) by 30.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 91,400 shares of the biotechnology company’s stock after buying an additional 21,500 shares during the period. BNP Paribas Financial Markets owned 0.22% of Evogene worth $69,000 as of its most recent SEC filing. Institutional investors and hedge funds own 10.40% of the company’s stock.

About Evogene

(Get Free Report)

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.

Featured Articles

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.